Resource Centre
Our aim is to provide easy access to the latest, most credible, information about pharmacogenomics in the UK in our Resource Centre.
Pharmacogenomics in the News | Pharmacogenomics Research | Pharmacogenomics Education
The Pharmaceutical Journal
May 2023.
Pharmacogenomic testing pilot to start in general practice from June 2023
The pilot will test patients at several NHS GP practices when they start a new statin, certain antidepressants or proton pump inhibitors to ensure they are on the right medication and not at risk of side effects.
The Lancet – UPGx-PREPARE Study
February 2023
World's largest study to date on the application of pharmacogenetic information shows that adaptation of medication to DNA variants leads to 30% fewer side effects
The study published in the journal The Lancet, is the first to show the success rates of managing the prescribing of drugs based on a person's genetic information.
From a genetic perspective, ‘one size fits all’ is a very much outdated view for prescribing medicines. Our genetic differences mean that patients can respond very differently the same drug.
Personalising treatment is the next stage in providing better patient outcomes and the ‘right medicine, right dose, first time’ becomes the new standard in medicine.
The Lancet study* showed that patients whose medication is adjusted according to their DNA had 30% less serious side effects than patients who were prescribed a standard dose of medication. About 7,000 patients from seven European countries were examined in various medical specialties, mainly patients treated in the fields of oncology, cardiology, psychiatry and general medicine.
Mantara Health works closely with Frankfurt based digital health-genomics company bio.logis led by human genetics specialist and founder Prof. Daniela Steinberger, in order to develop the Mantara DNA PGx Test in the UK.
bio.logis digital health and UPGx
Our partners, bio.logis digital health have compiled a comprehensive list of available literature on pharmacogenomics as part of their work on the UPGx PREPARE study.
You can access it here: https://www.biologis.com/solutions/Literature
University of Liverpool
The Department of Molecular and Clinical Pharmacology at the University of Liverpool is one of the world's leading research centres in the field of pharmacogenetics and pharmacogenomics. Led by the NHS Chair of Pharmacogenetics, Professor Sir Munir Pirmohamed, the team in Liverpool have been responsible for a significant body of research.
You can access their body of work here: https://www.liverpool.ac.uk/systems-molecular-and-integrative-biology/research/groups/pharmacogenetics/publications/
UPGx Study
The Ubiquitous Pharmacogenomics study (UPGx) has been taking place since 2016, looking into the effectiveness of using pre-emptive pharmacogenomic testing prior to prescribing new medications. Designed by seven of the top European pharmacogenomics experts, including the UK's own NHS Chair of Pharmacogenetics, Professor Sir Munir Pirmohamed, early indications from the study show that there is a significant reduction in the incidence of adverse drug reactions when pharmacogenomic testing is carried out prior to prescribing.
Full details of the study can be found at https://upgx.eu.
Please see updated study above (February 2023)